Literature DB >> 2731314

Intracellular metabolites of cisplatin in the rat kidney.

P Mistry1, C Lee, D C McBrien.   

Abstract

The appearance of low-molecular-weight metabolites of cisplatin in the cytosol of cells from the cortex and outer medulla of the rat kidney has been examined using HPLC up to 24 h following cisplatin administration. Comparison was made between these metabolites and those present in plasma, urine and liver. The effect of sodium chloride (NaCl) pretreatment, which is known to reduce cisplatin-induced nephrotoxicity, on these metabolites was also investigated. Platinum levels in the kidney cortex and medulla and the cytosol reached maximal levels within 1 h of i.p. injection of 5 mg/kg cisplatin. At least six platinum species, including cisplatin, were present 1 h post-dosing, with the principal species being the parent drug; all of these species were either neutral or negatively charged. Although the concentration of most of the platinum species fell with time, that of one species eluting before cisplatin rose, and by 24 h it was the major metabolite. Cisplatin and two other major cytosolic platinum species were also present in urine and plasma, both of which also contained a number of charged species that were absent from the cytosol. The liver cytosol contained at least five metabolites 1 h post-dosing, but, in contrast to the kidney cytosol at the same time, the predominant species was that eluting before cisplatin and not cisplatin itself. One of the metabolites in the cytosol and urine had the same retention time as an adduct of cisplatin with glutathione and with cysteine. Urinary samples also contained a metabolite coeluting with aquated cisplatin. Pretreatment of animals with NaCl significantly reduced the platinum concentration in the kidney, with a corresponding decrease in the cytosolic metabolites; this may have contributed significantly to the reduction in cisplatin-induced nephrotoxicity after NaCl pretreatment. NaCl also significantly reduced a possible aquated species present in the urine, which may also have contributed to the reduction in nephrotoxicity. The data suggest that cisplatin itself may be the nephrotoxic species, since it is the intracellular platinum compound present in highest concentration during the early critical period after its administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731314     DOI: 10.1007/bf00263124

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Subcellular localization of cis-dichlorodiammineplatinum(II) in rat kidney and liver.

Authors:  D D Choie; A A del Campo; A M Guarino
Journal:  Toxicol Appl Pharmacol       Date:  1980-09-15       Impact factor: 4.219

2.  Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration.

Authors:  C L Litterst
Journal:  Toxicol Appl Pharmacol       Date:  1981-10       Impact factor: 4.219

3.  Cisplatin metabolites: a method for their separation and for measurement of their renal clearance in vivo.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1983-01-01       Impact factor: 5.858

4.  Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model.

Authors:  R F Borch; M E Pleasants
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

5.  Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide.

Authors:  Z H Siddik; F E Boxall; K R Harrap
Journal:  Anal Biochem       Date:  1987-05-15       Impact factor: 3.365

6.  High-performance liquid chromatographic separation of platinum complexes containing the cis-1,2-diaminocyclohexane carrier ligand.

Authors:  S K Mauldin; F A Richard; M Plescia; S D Wyrick; A Sancar; S G Chaney
Journal:  Anal Biochem       Date:  1986-08-15       Impact factor: 3.365

7.  A study of the protective effect of chloride salts on cisplatin nephrotoxicity.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

8.  Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1984-10-01       Impact factor: 5.858

9.  The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.

Authors:  Z H Siddik; D R Newell; F E Boxall; K R Harrap
Journal:  Biochem Pharmacol       Date:  1987-06-15       Impact factor: 5.858

10.  Time course of the binding of platinum to subfractions of the kidney cytosol in the cisplatin-treated rat.

Authors:  R Mason; S Hogg; I R Edwards
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1986-04
View more
  14 in total

1.  Sorghum [Sorghum bicolor (L.) Moench] leaf sheath dye protects against cisplatin-induced hepatotoxicity and oxidative stress in rats.

Authors:  Adedayo O Ademiluyi; Ganiyu Oboh; Oluwaseun J Agbebi; Aline A Boligon; Margareth L Athayde
Journal:  J Med Food       Date:  2014-12       Impact factor: 2.786

2.  Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.

Authors:  Lauren M Aleksunes; Michael J Goedken; Cheryl E Rockwell; Juergen Thomale; Jose E Manautou; Curtis D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

3.  Alpha-linolenic acid confers protection on mice renal cells against cisplatin-induced nephrotoxicity.

Authors:  Erman Salih İstifli; Erkan Demir; Halil Mahir Kaplan; Kıvılcım Eren Ateş; Figen Doran
Journal:  Cytotechnology       Date:  2019-08-01       Impact factor: 2.058

Review 4.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Cisplatin nephrotoxicity: molecular mechanisms.

Authors:  Marie H Hanigan; Prasad Devarajan
Journal:  Cancer Ther       Date:  2003

6.  Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.

Authors:  D C Thompson; A Vaisman; M K Sakata; S D Wyrick; D J Holbrook; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.

Authors:  H P Hofs; D J Wagener; V De Valk-Bakker; H Van Rennes; D De Vos; W H Doesburg; H C Ottenheijm; W J De Grip
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

8.  Long-term pharmacokinetic behavior of platinum after cisplatin administration.

Authors:  E Gamelin; P Allain; P Maillart; A Turcant; R Delva; A Lortholary; F Larra
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses.

Authors:  P F Carfagna; A Poma; S D Wyrick; D J Holbrook; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 10.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.